Skip to main content

Advertisement

SpringerLink
Log in

Cancer-targeting antibody–drug conjugates drive dealmaking frenzy

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Improved linker technologies and broadening payload options mark a coming of age for these precision cancer therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. London, UK

    Melanie Senior

Authors
  1. Melanie Senior
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Senior, M. Cancer-targeting antibody–drug conjugates drive dealmaking frenzy. Nat Biotechnol 42, 362–366 (2024). https://doi.org/10.1038/s41587-024-02168-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-024-02168-5

  • Springer Nature America, Inc.

Search

Navigation